SC
AUTL

Stempoint Capital’s Autolus Therapeutics AUTL Stock Holding History

Stempoint Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-250,000
Closed -$68.8K – 49
2024
Q1 		$68.8K Buy
+250,000
New +$1.56M 0.02% 58

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Stempoint Capital's AUTL Position: Q4 2024 in Review

Stempoint Capital sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 2,616,602 shares — an estimated $9.5M sold.

Stempoint Capital first reported a position in AUTL in Q4 2023 and held it in 4 quarters. The position peaked at $18.9M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • Stempoint Capital reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Stempoint Capital sold 2,616,602 Autolus Therapeutics shares in Q4 2024, an estimated $9.5M.
  • Stempoint Capital first reported a position in Autolus Therapeutics in Q4 2023 and held it in 4 quarters.
  • Stempoint Capital's Autolus Therapeutics position peaked at $18.9M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.